Press Releases

Date Title  
Toggle Summary Natera and LifeLabs Announce Agreement for Panorama™ Non-Invasive Prenatal Test (NIPT) in Canada
SAN CARLOS, Calif. , April 24, 2015 / PRNewswire / -- Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services ("LifeLabs") today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using
Toggle Summary Study Published in the Journal Science Identifies the First Genetic Variant Directly Correlated to Mitotic-Origin Aneuploidy in Human Embryos
- Study analyzed over 20,000 unique embryos using Spectrum™ Preimplantation Genetic Screening from Natera - SAN CARLOS, Calif. , April 15, 2015 / PRNewswire / -- Natera, Inc., a leader in non-invasive genetic testing, announced the publication of a study in the current issue of Science , which
Toggle Summary Natera, Inc., Non-Invasive Genetic Testing Leader, Secures $55 Million in Private Financing
SAN CARLOS, Calif. , April 6, 2015 / PRNewswire / -- Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures.
Toggle Summary Natera Receives New York State Laboratory Permit for Its Portfolio of Next-Generation Preconception and Prenatal Genetic Tests
Approval Includes the Panorama™ Non-Invasive Prenatal Test, Preimplantation Genetic Diagnosis (PGD) and Non-Invasive Prenatal Paternity Testing Natera, a leading innovator in prenatal genetic testing, today announced that the New York State Department of Health has issued a clinical laboratory
Toggle Summary Natera Names Susan Gross, M.D., Chief Medical Officer
Natera, a leading innovator in prenatal genetic testing, today announced the addition of Susan Gross, M.D., as the company’s first chief medical officer. She brings to Natera more than 25 years of experience in the field of prenatal genetics. The addition of Dr.
Toggle Summary DiagCor to Launch Natera’s Panorama™ Non-Invasive Prenatal Test in Hong Kong
Natera today announced that DiagCor, a manufacturer of in-vitro diagnostic products and service provider of clinical diagnostic tests, has signed an agreement to launch Natera’s Panorama™ non-invasive prenatal screening test (NIPT) in Hong Kong. Panorama uses a simple blood draw from the mother to
Toggle Summary Hospital Israelita Albert Einstein and Natera Partner to Offer Panorama™, Natera’s Non-Invasive Prenatal Test for Detection of Chromosomal Abnormalities
Leading South American Hospital to Provide Test with Ability to Detect Trisomy 21, 18 and 13, Monosomy X, Triploidy, Vanishing Twins and Gender at Nine Weeks Gestation Hospital Israelita Albert Einstein and Natera, a leading innovator in prenatal genetic testing, today announced a partnership to
Toggle Summary Natera’s Non-Invasive Prenatal Test, Panorama™, to be Offered as Part of the California Prenatal Screening Program
Women with Positive Serum Screening Results Through the California Prenatal Screening Program Will Have Access to Panorama at No Cost Natera, a leading innovator in prenatal genetic testing, today announced that its non-invasive prenatal test (NIPT), PanoramaTM, will now be available to expecting
Toggle Summary Natera and Médica Fértil Announce Birth of First Baby in Mexico to be Screened with Non-Invasive Prenatal Test, Panorama™
Oct. 29, 2013 – Natera, a leading innovator in prenatal genetic testing, and Médica Fértil today announced the birth of the first baby in Mexico whose mother was screened with PanoramaTM, Natera’s non-invasive prenatal test. Panorama was launched in March 2013 for the detection of trisomy 21 (Down
Toggle Summary Natera Selected as a 2013 Fierce 15 Device and Diagnostic Company
Annual Award by FierceMedicalDevices Recognizes Most Promising Private Companies in Med Tech Space Natera, a leading innovator in prenatal genetic testing, today announced that it has been named by FierceMedicalDevices as a 2013 Fierce 15 device and diagnostic company, designating it as one of the

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.